Listen to this informative panel discussion about the use of site specific immunomodulators (SSIs), an investigational treatment aimed at stimulating the immune system to reverse the chronic inflammation underlying Crohn’s disease.
Panel includes:
Gastroenterologist Dr. Brian Bressler, Principal Investigator of Qu Crohn’s Trial
Qu Biologics’ founder and CEO, Dr. Hal Gunn
Qu Biologics’ Chief Medical Officer, Dr. Simon Sutcliffe
Gastroenterology Panel Discussion